Connected Insulin Pen Reporting for Accurate Diabetes Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Individuals with diabetes often fail to monitor glucose levels frequently due to inconvenience, pain, and cost, leading to inaccurate insulin dosing and poor glycemic control, with existing systems lacking integration of glucose data with insulin dosing and presenting data in difficult-to-read formats.
Innovation Solution
An integrated diabetes management system that includes an analyte monitoring device, medication delivery device, reader device, and reporting software, enabling easy data transfer and presenting glucose data to identify poor dose concordance and glycemic control, with user-specific data sharing and storage options.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If manual logging of insulin doses is used, then patients can track their dosing, but it requires huge time commitment and results in inaccurate dosing logs
Solution Approach 1:
The insulin pen automatically logs dosing information without requiring patient intervention. The device self-monitors and records the insulin dose administered, eliminating the need for manual patient logging while ensuring accurate dosing records are captured and stored.
Solution Approach 2:
The patent replaces the mechanical manual logging process with an electronic automated system. The connected insulin pen uses electronic sensors and digital record-keeping to automatically capture dosing data, substituting the manual writing or typing process with an automated electronic logging mechanism.
2Ease of operation
If connected insulin pens automatically log doses, then dosing is tracked without user action, but the data is presented in tabular form that is difficult to read and interpret
Solution Approach 1:
The patent transforms the flat tabular data presentation into a multi-dimensional visual format using graphs and charts. The dosing data is displayed with temporal, dosing amount, and glycemic control dimensions simultaneously visible, allowing patients to interpret the data easily without having to navigate complex tables.
Solution Approach 2:
The system uses color-coded visual indicators to represent different aspects of dosing and glycemic control. Colors are used to highlight trends, alert to patterns requiring attention, and make the data immediately interpretable at a glance, transforming the colorless tabular data into an intuitive visual language.
3Reliability
If glucose monitoring frequency is increased, then glycemic control improves, but inconvenience, pain, and cost increase
Solution Approach 1:
The system provides continuous automated feedback by monitoring glucose levels and automatically adjusting or recommending insulin dosing. This closed-loop feedback mechanism maintains reliable glycemic control without requiring frequent manual patient intervention, as the system automatically processes the monitoring data and provides actionable dosing recommendations.
Solution Approach 2:
The patent introduces an intermediary automated system that mediates between glucose monitoring and insulin dosing decisions. This intermediary processing layer analyzes monitoring data and translates it into dosing recommendations, reducing the direct burden on patients while maintaining effective glycemic control through data-driven dosing adjustments.
4Adaptability or versatility
If multiple drugs with different delivery frequencies and routes are used, then diabetes management is comprehensive, but cognitive burden increases and dose regimen concordance decreases
Solution Approach 1:
The system is designed as a universal platform that can manage multiple types of diabetes medications with different delivery frequencies and routes through a single integrated interface. The device accommodates various drug types and administration schedules within one system, eliminating the need for patients to mentally track multiple separate regimens and reducing cognitive burden while maintaining comprehensive management.
Data Source
AI summary
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user is not signed into an account. The types of data shared and/or stored when the user is not signed into an account may differ from the types of data shared and/or stored when the user is signed into an account.